Conditions: Neoplasm Metastasis Lymphoma
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 12
Healthy volunteers: no

Brief summary:
The main purpose of this study is to evaluate safety and side effects of LY2835219 in Japanese participants with advanced cancer.

Detailed description:

Arms:
arm 1: 100 milligram (mg) abemaciclib administered orally every 12 hours (Q12H) in 28 day cycles. (Cycle 1 = 32 days.) Participants remained on treatment until discontinuation criteria were met. arm 2: 150 mg abemaciclib administered orally Q12H in 28 day cycles. (Cycle 1 = 32 days.) Participants remained on treatment until discontinuation criteria were met. arm 3: 200 mg abemaciclib administered orally Q12H in 28 day cycles. (Cycle 1 = 32 days.) Participants remained on treatment until discontinuation criteria were met.

Interventions: intervention 1: LY2835219
Intervention descriptions: intervention 1: Administered orally

Protocol document: